Company intelligence / Profile preview
OroGen BioSciences
- Ownership
- Private
- Development stage
- Commercial
Overview
Orogen is pioneering a drug discovery approach that integrates proprietary DNA encoded libraries with AI/machine learning and molecular simulations. The company aims to rapidly identify, optimize, and select novel small molecule candidates for serious unmet medical needs in inflammatory, immune, and other diseases. Recent partnerships have enhanced their data-driven capabilities for predictive modeling in drug discovery. No published clinical results yet—focus remains on preclinical innovation.
- Therapeutic areas
- Immunology
- Modalities
- Small moleculesDNA Encoded Libraries (DEL)
- Industry
- Biotech
Drug pipeline
11 assets10 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on OroGen BioSciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OroGen BioSciences.